Özet:

 Abstract:  Introductıon: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) aim to excise all macroscopic diseases and to extend the survival period of patients with heated (>40 °C) chemotherapeutic agent treatments administered directly to the peritoneal cavity. The primary objective of our study was to describe the clinical features, surgical procedures, and complications of gynecologic cancer patients; its secondary objective was to determine the short term general and disease-free lifespan of the patients.   Material and method: Twenty-five patients who underwent HIPEC following CRS due to gynecologic cancer between May 2015 and October 2018 at the Gynecology Oncology Clinic of IU Istanbul Faculty of Medicine were evaluated retrospectively. Surgical complications were classified by Clavien - Dindo criteria.   Results: Out of the 25 patients, 23 were in the SRC + HIPEC group following recurrence while two were in the interval debulking surgery + HIPEK group following neoadjuvant chemotherapy. Of the patients, 23 had ovarian cancer while two had serous endometrial cancer, and the majority of the patients with ovarian cancer were platinum-resistant. The mean age of the patients was 57 (33-74) and the mean duration of SRC was 192 (90- 420) minutes.  During the mean follow-up of twelve (one- thirty-five) months, one-year overall survival was 72% and three-year survival was 8% in the patients who underwent SRC + HIPEC. Evaluation of 14 patients with platinum-resistant recurrent EOC revealed mean survival as 12.2 months and disease-free survival as 4.4 months.  Three patients had peri-operative severe morbidity (one patient had anastomosis leakage after bowel resection, and two patients had pelvic abscess/hematoma) while in one patient, sepsis-related mortality occurred after anastomotic leakage. Besides, first and second-degree complications were found to be the most common causes of morbidity due to HIPEC.   Conclusıon: SRC and HIPEC are applied experimentally in patients with advanced stage ovarian and endometrial cancer, and the best results are obtained if there are no visible tumors. Considering the platinum-resistant patient group and the inadequacy of the available treatment options for this patient group, our short-term results are promising. Furthermore, the frequency of the side effects reported in our study was similar to the that of in previous studies. Our research, which has acceptable side-effect data and reasonable survival outcomes, seems to be encouraging for this treatment that is increasingly becoming widespread in our country.

Anahtar Kelimeler: